The genetics of small-vessel disease

A Bersano1, S Debette, E R Zanier

  • 1Department of Emergency Neurology, IRCCS C. Mondino National Neurological Institute Foundation, Via Mondino 2, 27100 Pavia, Italy. anna.bersano@gmail.com

Insights

Genetic factors likely contribute to cerebral small-vessel disease (SVD), a cause of stroke and dementia. Identifying these genetic links is crucial for understanding SVD pathogenesis and developing new treatments.

Area of Science:

  • Neurology
  • Genetics
  • Vascular Biology

Background:

  • Cerebral small-vessel disease (SVD) is a significant cause of stroke, dementia, and mortality.
  • SVD manifests neuroradiologically through ischemia (leukoaraiosis, lacunar infarction) and microhemorrhages (cerebral microbleeds, intracerebral hemorrhage).
  • Evidence suggests genetic factors play a role in SVD pathogenesis, though it is complex and multifactorial.

Purpose of the Study:

  • To explore the role of genetic factors in the pathogenesis of cerebral small-vessel disease (SVD).
  • To identify potential genetic susceptibility factors for SVD to inform therapeutic strategies.
  • To understand how genetic insights into monogenic SVD forms can illuminate broader SVD mechanisms.

Main Methods:

  • Review of family and twin studies supporting genetic contributions to SVD.
  • Analysis of findings from monogenic SVD conditions.
  • Evaluation of results from candidate gene and genome-wide association studies (GWAS).

Main Results:

  • Monogenic disorders, while rare, offer insights into SVD pathogenesis.
  • Previous genetic association studies (candidate gene, GWAS) have not yielded convincing results for complex SVD.
  • Methodological limitations like phenotyping and sample size may explain the lack of clear genetic associations.

Conclusions:

  • Identifying genetic susceptibility factors for SVD is essential for advancing our understanding of its pathogenesis.
  • Future research requires large-scale collaborative efforts, robust replication, and novel genetic approaches.
  • Unraveling the genetic basis of SVD is key to developing targeted therapies for cognitive decline and stroke disability.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...